Baumann Hannah M, Dybeck Eric, McClendon Christopher L, Pickard Frank C, Gapsys Vytautas, Pérez-Benito Laura, Hahn David F, Tresadern Gary, Mathiowetz Alan M, Mobley David L
Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, California 92697, United States.
Pfizer Worldwide Research, Development, and Medical, 1 Portland Street, Cambridge, Massachusetts 02139, United States.
J Chem Theory Comput. 2023 Aug 8;19(15):5058-5076. doi: 10.1021/acs.jctc.3c00282. Epub 2023 Jul 24.
Binding free energy calculations predict the potency of compounds to protein binding sites in a physically rigorous manner and see broad application in prioritizing the synthesis of novel drug candidates. Relative binding free energy (RBFE) calculations have emerged as an industry-standard approach to achieve highly accurate rank-order predictions of the potency of related compounds; however, this approach requires that the ligands share a common scaffold and a common binding mode, restricting the methods' domain of applicability. This is a critical limitation since complex modifications to the ligands, especially core hopping, are very common in drug design. Absolute binding free energy (ABFE) calculations are an alternate method that can be used for ligands that are not congeneric. However, ABFE suffers from a known problem of long convergence times due to the need to sample additional degrees of freedom within each system, such as sampling rearrangements necessary to open and close the binding site. Here, we report on an alternative method for RBFE, called Separated Topologies (SepTop), which overcomes the issues in both of the aforementioned methods by enabling large scaffold changes between ligands with a convergence time comparable to traditional RBFE. Instead of only mutating atoms that vary between two ligands, this approach performs two absolute free energy calculations at the same time in opposite directions, one for each ligand. Defining the two ligands independently allows the comparison of the binding of diverse ligands without the artificial constraints of identical poses or a suitable atom-atom mapping. This approach also avoids the need to sample the unbound state of the protein, making it more efficient than absolute binding free energy calculations. Here, we introduce an implementation of SepTop. We developed a general and efficient protocol for running SepTop, and we demonstrated the method on four diverse, pharmaceutically relevant systems. We report the performance of the method, as well as our practical insights into the strengths, weaknesses, and challenges of applying this method in an industrial drug design setting. We find that the accuracy of the approach is sufficiently high to rank order ligands with an accuracy comparable to traditional RBFE calculations while maintaining the additional flexibility of SepTop.
结合自由能计算以物理严谨的方式预测化合物与蛋白质结合位点的亲和力,并在确定新型候选药物合成的优先级方面有广泛应用。相对结合自由能(RBFE)计算已成为一种行业标准方法,用于对相关化合物的亲和力进行高度准确的排序预测;然而,这种方法要求配体共享一个共同的支架和共同的结合模式,限制了该方法的适用范围。这是一个关键限制,因为在药物设计中,对配体进行复杂修饰,尤其是核心跳跃,非常常见。绝对结合自由能(ABFE)计算是一种可用于非同类配体的替代方法。然而,由于需要在每个系统中对额外的自由度进行采样,例如对打开和关闭结合位点所需的重排进行采样,ABFE存在收敛时间长的已知问题。在这里,我们报告了一种用于RBFE的替代方法,称为分离拓扑(SepTop),它通过允许配体之间进行大的支架变化,同时收敛时间与传统RBFE相当,克服了上述两种方法中的问题。这种方法不是只对两个配体之间不同的原子进行突变,而是同时在相反方向上进行两次绝对自由能计算,每个配体一次。独立定义两个配体允许比较不同配体的结合,而无需相同构象或合适的原子-原子映射的人为限制。这种方法还避免了对蛋白质未结合状态进行采样的需要,使其比绝对结合自由能计算更有效。在这里,我们介绍了SepTop的一种实现。我们开发了一个通用且高效的协议来运行SepTop,并在四个不同的、与药物相关的系统上展示了该方法。我们报告了该方法的性能,以及我们在工业药物设计环境中应用此方法的优势、劣势和挑战的实际见解。我们发现,该方法的准确性足够高,能够以与传统RBFE计算相当的准确性对配体进行排序,同时保持SepTop的额外灵活性。